Clinical Research Support
Clinical Trials Education Office (CTEO)
Clinical Investigator Education Series
This series is designed for DF/HCC or Harvard affiliated clinicians who are or will be assuming principal investigator responsibilities for clinical trials. Registration is encouraged and can be done by accessing the on-line registration form located at the end of each session description.
Harvard Medical School has designated each session for Category 1 CMEs as indicated. The Accreditation Council for Continuing Medical Education has accredited Harvard Medical School to provide continuing education for physicians.
Contact the CTEO at CTEO@dfci.harvard.edu if you have any questions or would like more information.
DF/HCC and Cancer Care in 2015
Personalized cancer medicine is our Cancer Center's Evantual care goal. Realizing this vision will require a number of important institutional changes that will affect the way we do basic and clinical research. This session will provide a glimpse of things to come.
Presented by Barrett Rollins, MD, PhD, Chief Scientific Officer for Dana-Farber Cancer Institute
August 22, 2008 10am-11am Dana 1620 Register
This session will also be videobroadcast to MGH CCPO 326 Cambridge St. 2nd Floor Conference Room
PI-Initiated Multi-Center Trials-Jeffrey Clark, MD
This session is specifically targeted at those individuals who are actively or will be responsible for an investigator-initiated multi-center trial. This session will address the considerations in the planning, design and conduct of a multi-center trials, as well as the responsibilitiesof key personnel and best practices for trial management.
Registration suggested: Register
September 26, 2008 10:00am-11:00am Dana 1620
**This session will also be video broadcast to MGH CCPO Conference Room**
CME : Category 1 Credit Provided
Considerations for Choosing Among Types of Phase II Designs
We will review common designs for Phase II studies, discuss their statistical properties, and examine issues with respect to choice of endpoint, concurrent versus historical control, and early evaluations for efficacy and/or futility. Special emphasis will be given to the advantages and disadvantages of multi-arm randomized phase II trials.
Presented by Paul Catalano, ScD, Senior Lecturer on Biostatistics
June 26, 2009 10am-11am Dana 1620 Register
This session will also be videobroadcast to MGH CCPO 326 Cambridge St. 2nd Floor Conference Room
CME: Category 1 Credit Provided
